News Release

Printer Friendly Version View printer-friendly version << Back
 
ProQR to Participate in a Cystic Fibrosis Panel Discussion during the JMP Securities Life Science Conference

13 June 2017 at 7:01 AM EDT

LEIDEN, The Netherlands, June 13, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that Daniel de Boer, Chief Executive Officer, will participate in a panel discussion focused on emerging treatment options in cystic fibrosis during the JMP Securities Life Science Conference on June 20th at 8:30am. The conference is being held at The St. Regis in New York, NY, USA.   

About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases such as cystic fibrosis, Leber’s congenital amaurosis Type 10 and dystrophic epidermolysis bullosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. 
*Since 2012*

ProQR Therapeutics N.V.:
Smital Shah
Chief Financial Officer
T: +1 415 231 6431
ir@proqr.com

Primary Logo

ProQR Therapeutics N.V.